Candid Therapeutics Scores Nasdaq Listing and Oversubscribed $505M financing
March 2, 2026
Our collective clinical, scientific and investment expertise drives long-term conviction in our portfolio companies
We're Friendly Capital
We provide our companies with founder-aligned terms and patient, flexible capital
We have Conviction
Our rigorous pre-investment due diligence ensures long-term commitment to our companies
We Offer Unique Support
Our companies leverage the LifeSci Partners network to accelerate business development and drive value creation
The LifeSci team played an integral role in the formation and successful launch of Engage Therapeutics. At all times, I considered them part of my team. From the beginning, LifeSci guided me through the investor story, outreach process and strategy for closing.
We are honored by the magnitude of support from such an impressive syndicate of investors, especially during these turbulent times.
"LifeSci Ventures has been a trusted, steady, and value adding partner across three of my companies and they will continue to be top of mind for me as an investor to include in any future deals."
Paul Yook
Managing Partner & CIO
Ryan Cinalli, Ph.D.
Partner & CSO
Ira Kalfus, M.D.
Venture Partner
Brittany Amendola, C.P.A.
Chief Financial Officer
Jeff Seo
Business Development
August 2020, Series D-1
Science 37 is a decentralized CRO making the promise of v...
March 2019, Series A April 2020, Series B
Erasca is a San Diego based biotech company creating a new generation of onc...
May 2019, Series C
Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disea...
January 2019, Series B
Beta Bionics is a medical device company developing the breakthrough iLet system which combines...
December 2018, Series B
Akero is a biotechnology company focused on serious metabolic diseases with a lead program, AK...
June 2018, Series B
Attune is a clinical-stage biotechnology company focused on novel small-molecule therapeutics for...
June 2018, Series C
Metacrine is a San Diego based biotechnology company with exceptional chemistry capabilities and a...
March 2018, Series B
Orasis is a clinical-stage pharmaceutical company developing an innovative eye drop for the treat...
March 2018, At-the-Market
Nasdaq: NVUS
Novus is a specialty pharma company focused on disorders of the near, nose...
January 2018, Series D
November 2018, RTO
Columbia Care is one of the largest medical cannabis manufacturers and...
November 2017, Series B
July 2018, IPO - Nasdaq: ALLK
Allakos is developing AK002, a first-in-class antibody...
March 2017, Series B
January 2018, NASDAQ: RCKT
Rocket Pharma is developing...
September 2017, Series A
Engage is developing Staccato® Alprazolam, a small, easy-to-use hand-held drug-device com...
Dr. Kalfus was Chief Medical Officer at Thar Pharmaceuticals until its acquisition by Grunenthal in 2016. He was previously Vice President of Medical Affairs at Lev Pharmaceuticals, where he led the clinical development for Cinryze, the first HAE prophylaxis therapy, approved by the FDA in 2008. Upon the acquisition of Lev by ViroPharma Inc. in 2008, he consulted on the Cinryze commercial launch and expansion as well as investor relations activities for ViroPharma. Dr. Kalfus is consulting Medical Director at RedHill Biopharma Ltd. and directs two phase III clinical programs. His other positions have included Aetna/US Healthcare (Medical Director), Hillside Medical Associates (Internist), and Long Island Jewish Medical Center (President of the Staff Society and Chairman of Performance Improvement). Dr. Kalfus completed residency in Internal Medicine at Long Island Jewish Medical Center and graduated from Albert Einstein College of Medicine with an M.D. and Columbia University with a B.A. in Biology.
Visit Homepage